Author

Nithya Paruchuri

The Ohio State University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Dawei ZhouiD· 2 shared Guillaume N. FichesiD· 2 shared Jinshan HeiD· 2 shared Netty G. SantosoiD· 2 shared Suha Eleya· 2 shared Thurbu Tshering Lepcha· 2 shared Darrion Mitchell· 1 shared J F ZhuiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Dawei ZhouORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeted RNA degradation of HIV-1 TAR element at 5'UTR by CRISPR-Cas13X blocks HIV-1 lytic reactivation

Thurbu Tshering Lepcha, Dawei Zhou, Guillaume N. Fiches, Nithya Paruchuri, Jinshan He, Kateepe ASN Shanaka, Yan Liu, Suha Eleya, Netty G. Santoso, Jian Zhu

This study uses CRISPR-Cas13X to target HIV-1 TAR RNA, inhibiting viral reactivation and reducing viral load in infected cells.

bioRxiv · Oct 15, 2026 · PreprintMicrobiology

Targeting NAT10 Activates Tumor-Intrinsic Immunity and Suppresses Tumor Progression in Head and Neck Squamous Cell Carcinoma

Thurbu Tshering Lepcha, Nithya Paruchuri, Dawei Zhou, Guillaume N. Fiches, Jinshan He, K.A.S.N. Shanaka, Liu Y, Suha Eleya, Nischal Koirala, J F Zhu, Darrion Mitchell, W Zhao, Netty G. Santoso

This study identifies NAT10 as a suppressor of tumor-intrinsic immunity in HNSCC, showing that its inhibition enhances immune responses and suppresses tumor progression.

bioRxiv · Aug 8, 2026 · PreprintCancer Biology